December 16, 2015
The targeted, oral therapy crizotinib (Xalkori), has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have c-ros oncogene 1 (ROS1)-rearranged tumors.
December 10, 2015
The combination of radiation therapy plus cetuximab had higher rates of acute toxicity among patients with locally advanced squamous cell carcinoma of the head and neck compared with radiation therapy plus cisplatin.
December 04, 2015
Ahead of the 57th ASH Annual Meeting & Exposition, December 5–8, 2015, Jeffrey Tyner, PhD, discusses his latest research on screening tumor cells derived from cancer patients to help guide better treatment decisions.
November 12, 2015
Advanced lung cancer patients who have tumors with mutations in the epidermal growth factor receptor (EGFR) gene may benefit from the combination treatment of erlotinib standard therapy plus tivantinib.
November 10, 2015
The targeted therapy, nivolumab (Opdivo, Bristol Myers Squibb), improved median overall survival by 5.4 months among patients with previously treated renal cell carcinoma (RCC) compared to standard of care everolimus (Afinitor).
August 25, 2015
A complex high-dose combination therapy is tolerable and effective in patients with aggressive B-cell lymphoma that has spread to the central nervous system.
May 26, 2015
Patients with EGFR-positive, non-small cell lung cancer (NSCLC) typically respond well to EGFR-targeted therapy, but eventually these tumors become resistant, leaving patients few options other than palliative care.
March 11, 2015
Inherited variants in an androgen transporter gene may determine the time to progression (TTP) for men with prostate cancer receiving androgen deprivation therapy (ADT).
March 05, 2015
Researchers have shown that reprogramming T cells to target glioblastoma in mice resulted in control of these tumors.
February 24, 2015
Neither sunitinib nor sorafenib reduced disease recurrence in patients with locally advanced renal cell carcinoma (RCC) when these agents were given to patients as adjuvant therapy, according to the results of a new study.